11 September, 2024Joint poster with Sonova: Integrating NAMs into early-stage screening of novel materials
29 August, 2024Joint publication with L’Oréal: In vitro prediction of skin sensitizing potency using the GARDskin Dose-Response assay: A simple regression approach
18 April, 2024Joint poster with RIFM and IFF: In vitro Skin Sensitization Potency Prediction Performance on the RCPL list
19 March, 2024Joint publication with IFF and RIFM: GARDskin dose-response assay and its application in conducting Quantitative Risk Assessment (QRA) for fragrance materials using a Next Generation Risk Assessment (NGRA) framework
12 March, 2024Evaluation of the applicability of GARDskin to predict skin sensitizers in extracts from medical device materials
11 March, 2024Joint publication with Corteva Agriscience: GARD™skin and GARD™potency: A proof-of-concept study investigating applicability domain for agrochemical formulations
27 November, 2023Joint poster with Takasago: Determining safe use level for novel fragrance ingredients
2 November, 2023New scientific publication by ExxonMobil: Challenges integrating skin sensitization data for assessment of difficult to test substances
19 September, 2023Joint poster with ExxonMobil: Case study on UVCBs and Formulated Lubricant Products
19 March, 2023In vitro assays for assessment of the skin sensitization hazard and potency of isobornyl acrylate
19 March, 2023Joint poster with RIFM: Assessment of Reference Photoirritants and Photoallergens using GARD
18 November, 2022SenzaGen’s services are now available online through the Science Exchange Marketplace!
21 October, 2022Next Generation Risk Assessment (NGRA) using NAMs for skin sensitization: Reproducibility and precision of the GARDskin Dose-Response assay for PoD determination of fragrance chemicals.
21 October, 2022The use of the GARD®skin Dose-Response assay to assess skin sensitizing potency in developing novel fragrance ingredients
29 April, 2022The GARDskin Assay: Investigation of the Applicability Domain of Indirectly Acting Haptens
29 April, 2022Ability of the GARDskin assay to Predict Skin Sensitization Response in the Guinea Pig Maximization Test
29 April, 2022In vitro method for quantitative potency assessment of skin sensitizers during development of novel materials for intended use in medical devices
21 April, 2022Exploration of the GARDskin applicability domain: Indirectly acting haptens, hydrophobic substances and UVCBs
22 November, 2021Skin Sensitization Potency Assessments of Fragrance Materials using GARDskin Dose-Response
20 October, 2021Assessment of the skin sensitizing potential of pandemic-associated medical devices using the GARDskin Medical Device assay
24 September, 2021Quantitative assessment of sensitizing potency using a dose-response adaptation of GARDskin
30 August, 2021Reliable and Truly Animal-Free Skin Sensitization Testing – Adaption of the In vitro GARD™skin to Animal-Free Conditions
30 August, 2021The GARD™potency assay for potency-associated subclassification of chemical skin sensitizers – Rationale, method development and ring trial results of predictive performance and reproducibility
29 July, 2021Webcast: Positive scientific ESAC opinion on GARD®skin – paving the way for OECD validation and opens new commercial opportunities
9 July, 2021Leading cosmetic company tests ingredients with GARDskin Dose-Response to support product safety
15 April, 2021Applicability domain of the GARD™skin Medical Device test for in vitro skin sensitization testing of medical devices
15 April, 2021GARDskin and GARDpotency: a proof of concept study to investigate the applicability domain for agrochemical formulations
26 March, 2021SOT 2021 Recap: Spotlight on Dose-Response and the MDCPSS Best Overall Abstract Award Winner 🏅
20 November, 2020Applicability of GARD™skin for Accurate Assessment of Challenging Substances in the Context of Skin Sensitization Testing
21 October, 2020RIFM Principle Scientist Gretchen Ritacco speaks about SenzaGen and RIFM collaboration
6 July, 2020The GARDpotency assay for potency-associated subclassification of chemical skin sensitizers – Rationale, method development and ring trial results of predictive performance and reproducibility
6 February, 2020An integrated transcriptomic- and proteomic-based approach to evaluate the human skin sensitization potential of glyphosate and its commercial agrochemical formulations
21 May, 2019Validation of the GARD™skin assay for assessment of chemical skin sensitizers – ring trial results of predictive performance and reproducibility
21 April, 2019Evaluation of in vitro testing strategies for hazard assessment of the skin sensitization potential of “real‐life” mixtures: the case of henna‐based hair coloring products containing p‐phenylenediamine
17 October, 2018GARD™air – A novel assay for assessment of chemical respiratory sensitizers based on a genomic platform
19 September, 2018Inspelning samt transkript från telefonkonferens gällande ECVAMs utvärdering av GARDskin flyttad till våren 2019
9 September, 2018Exploration of the GARD applicability domain – Skin sensitization assessment of UVCBs
7 September, 2018SenzaGen hosts network meeting Understanding Biocompatibility of Medical Devices, October 2, at Medicon Village in Lund
3 September, 2018Predicting skin sensitizers with confidence – Using conformal prediction to determine applicability domain
24 August, 2018The use of GARDskin for sensitization evaluation of cosmetic ingredients and ‘real-life’ mixtures
20 August, 2018SenzaGen co-hosting international workshop on Skin Sensitization in Brazil 21st August 2018
28 May, 2018Seminar at the Swedish Parliamentary Animal Protection Forum in collaboration with Djurens Rätt (Animal Rights), The Body Shop and Cruelty Free International
16 May, 2018SenzaGen invited to speak at the Swedish Parliament Breakfast seminar Fråga Makten! (Ask the power) about how we stop animal testing in cosmetics
20 April, 2018The In Vitro assessment of Respiratory Sensitisation Potential of Electronic Cigarette Liquids
20 February, 2018Conclusive data on predictive performance of GARD™ in highly regarded scientific journal
17 October, 2017SenzaGen CEO Anki Malmborg Hager presents at Swetox conference on future research without animal testing
16 October, 2017Malin Lindstedt, founder of SenzaGen and GARD, is awarded the NYTÄNKAREN 2017 (INNOVATIVE THINKER 2017) prize by the Swedish foundation Research Without Animal Experiments
16 October, 2017Grundaren av SenzaGen och GARD, Malin Lindstedt, tilldelas priset som NYTÄNKAREN 2017 av stiftelsen Forska Utan Djurförsök
26 August, 2017Integrated hazard identification of chemical sensitizers using in vitro and in silico readouts – A comparative evaluation of predictive performance
30 June, 2017Meet us in Almedalen – The researchers behind the GARDtest and SenzaGen’s lab technicians on site.
6 March, 2017SenzaGen is presenting at hosted sessions at Society of Toxicology 56th Annual Meeting in Baltimore March 12-16, 2017
20 September, 2016GARD™ – the future of sensitization testing and safety assessment of chemicals using a genomic-based platform
15 September, 2016GARD™ – the future of sensitization testing and safety assessment of chemicals, using a genomics-based platform
24 August, 2016Anki Malmborg Hager elected one of the two most powerful people among Lund technology companies according to Rapidus ranking
10 March, 2016SenzaGen is presenting at a hosted session at Society of Toxicology 55th Annual Meeting in New Orleans March 15, 2016
15 April, 2015Almi Invest awards SenzaGen the prestigeous Annual Keywhole investment prize. “Årets titthålsinvestering”
30 December, 2011Signature biomarker analysis for prediction of skin sensitizers using a cell-based in vitro alternative to animal experimentation
